While Medicare Part D coverage has changed, XPHOZAH is available. Learn more
For US Healthcare Professionals Only
For US Healthcare Professionals Only
Salvatore ChillemiDr. Salvatore Chillemi discusses his clinical experience with XPHOZAH
North Georgia Kidney Specialist
Marietta, GA
Stuart M. SpragueDr. Stuart Sprague describes our new mechanistic understanding of phosphate absorption.
Glenn ChertowDr. Glenn Chertow explains how we may be underestimating the portion of patients with uncontrolled hyperphosphatemia.
Nelson KopytDr. Nelson Kopyt explains the crucial role of the paracellular pathway in phosphate absorption.
MOA
Learn how XPHOZAH works to specifically block paracellular phosphate absorption.
Nelson KopytDr. Nelson Kopyt outlines why XPHOZAH should be considered as a treatment option for patients with CKD on dialysis.
Andrew LazarDr. Andrew Lazar explains the recommended 30 mg BID dosing for XPHOZAH
William RaffoDr. William Raffo explains why XPHOZAH is recommended to be taken before the first and last meals of the day.
Salvatore ChillemiDr. Salvatore Chillemi discusses his clinical experience with XPHOZAH
Andrew LazarDr. Andrew Lazar explains why some patients may experience diarrhea while using XPHOZAH.
Andrew LazarDr. Andrew Lazar explains how to manage diarrhea while on XPHOZAH and what to expect while on treatment.
Experts are paid advisors of Ardelyx, Inc.
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.
XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
XPHOZAH is contraindicated in:
Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.
Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.
For additional safety information, please see full Prescribing Information.
